Clinical Trial Detail

NCT ID NCT02706691
Title Pan FGFR Kinase Inhibitor BGJ398 in Treating Patients With FGFR1-3 Translocated, Mutated, or Amplified Recurrent Head and Neck Cancer
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors University of Chicago
Indications

nasopharynx carcinoma

head and neck squamous cell carcinoma

Therapies

Infigratinib

Age Groups: adult senior

Additional content available in CKB BOOST